View Future GrowthRenol Polychem 과거 순이익 실적과거 기준 점검 4/6Renol Polychem은 연평균 47.8%의 비율로 수입이 증가해 온 반면, Chemicals 산업은 수입이 6.5% 증가했습니다. 매출은 연평균 35.1%의 비율로 증가했습니다. Renol Polychem의 자기자본이익률은 6.8%이고 순이익률은 9.1%입니다.핵심 정보47.77%순이익 성장률39.79%주당순이익(EPS) 성장률Chemicals 산업 성장률17.68%매출 성장률35.07%자기자본이익률6.84%순이익률9.15%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹6.83 (vs ₹9.10 in FY 2025)Full year 2026 results: EPS: ₹6.83. Revenue: ₹902.3m (up 44% from FY 2025). Net income: ₹82.5m (up 65% from FY 2025). Profit margin: 9.1% (up from 8.0% in FY 2025). The increase in margin was driven by higher revenue.공시 • May 27Renol Polychem Limited to Report Second Half, 2026 Results on May 29, 2026Renol Polychem Limited announced that they will report second half, 2026 results on May 29, 2026공시 • Nov 13Renol Polychem Limited to Report First Half, 2026 Results on Nov 13, 2025Renol Polychem Limited announced that they will report first half, 2026 results on Nov 13, 2025모든 업데이트 보기Recent updatesNew Risk • Jul 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (98% accrual ratio). Market cap is less than US$10m (₹611.7m market cap, or US$6.46m). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹6.83 (vs ₹9.10 in FY 2025)Full year 2026 results: EPS: ₹6.83. Revenue: ₹902.3m (up 44% from FY 2025). Net income: ₹82.5m (up 65% from FY 2025). Profit margin: 9.1% (up from 8.0% in FY 2025). The increase in margin was driven by higher revenue.공시 • May 27Renol Polychem Limited to Report Second Half, 2026 Results on May 29, 2026Renol Polychem Limited announced that they will report second half, 2026 results on May 29, 2026Valuation Update With 7 Day Price Move • May 21Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹109, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 21x in the Chemicals industry in India.New Risk • May 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹965.6m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (65% accrual ratio). Market cap is less than US$10m (₹965.6m market cap, or US$9.97m).공시 • Nov 13Renol Polychem Limited to Report First Half, 2026 Results on Nov 13, 2025Renol Polychem Limited announced that they will report first half, 2026 results on Nov 13, 2025Valuation Update With 7 Day Price Move • Oct 30Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹90.00, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 26x in the Chemicals industry in India.공시 • Aug 06Renol Polychem Limited has completed an IPO in the amount of INR 257.67 million.Renol Polychem Limited has completed an IPO in the amount of INR 257.67 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 148,800 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 384,000 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 256,800 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 349,200 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,315,200 Price\Range: INR 105 Transaction Features: Regulation SBoard Change • Aug 06High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Executive Director Naitik Harsoda is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.매출 및 비용 세부 내역Renol Polychem가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NSEI:RNPL 매출, 비용 및 순이익 (INR Millions)날짜매출순이익일반관리비연구개발비31 Mar 269028316031 Dec 258206713030 Sep 257375211030 Jun 25678518031 Mar 25626506031 Mar 2465151031 Mar 2341972031 Mar 22268210양질의 수익: RNPL의 비현금 수익 수준이 높습니다.이익 마진 증가: RNPL의 현재 순 이익률 (9.1%)은 지난해 (8%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: RNPL의 수익은 지난 5년 동안 연평균 47.8%로 크게 증가했습니다.성장 가속화: 지난 1년간 RNPL 의 수익 증가율(65.2%)은 연간 평균(47.8%)을 초과합니다.수익 대 산업: RNPL의 지난 1년 수익 증가율(65.2%)은 Chemicals 업계의 13.6%를 상회했습니다.자기자본이익률높은 ROE: RNPL의 자본 수익률(6.8%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/02 17:26종가2026/07/02 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Renol Polychem Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹6.83 (vs ₹9.10 in FY 2025)Full year 2026 results: EPS: ₹6.83. Revenue: ₹902.3m (up 44% from FY 2025). Net income: ₹82.5m (up 65% from FY 2025). Profit margin: 9.1% (up from 8.0% in FY 2025). The increase in margin was driven by higher revenue.
공시 • May 27Renol Polychem Limited to Report Second Half, 2026 Results on May 29, 2026Renol Polychem Limited announced that they will report second half, 2026 results on May 29, 2026
공시 • Nov 13Renol Polychem Limited to Report First Half, 2026 Results on Nov 13, 2025Renol Polychem Limited announced that they will report first half, 2026 results on Nov 13, 2025
New Risk • Jul 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (98% accrual ratio). Market cap is less than US$10m (₹611.7m market cap, or US$6.46m). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).
Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹6.83 (vs ₹9.10 in FY 2025)Full year 2026 results: EPS: ₹6.83. Revenue: ₹902.3m (up 44% from FY 2025). Net income: ₹82.5m (up 65% from FY 2025). Profit margin: 9.1% (up from 8.0% in FY 2025). The increase in margin was driven by higher revenue.
공시 • May 27Renol Polychem Limited to Report Second Half, 2026 Results on May 29, 2026Renol Polychem Limited announced that they will report second half, 2026 results on May 29, 2026
Valuation Update With 7 Day Price Move • May 21Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹109, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 21x in the Chemicals industry in India.
New Risk • May 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹965.6m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (65% accrual ratio). Market cap is less than US$10m (₹965.6m market cap, or US$9.97m).
공시 • Nov 13Renol Polychem Limited to Report First Half, 2026 Results on Nov 13, 2025Renol Polychem Limited announced that they will report first half, 2026 results on Nov 13, 2025
Valuation Update With 7 Day Price Move • Oct 30Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹90.00, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 26x in the Chemicals industry in India.
공시 • Aug 06Renol Polychem Limited has completed an IPO in the amount of INR 257.67 million.Renol Polychem Limited has completed an IPO in the amount of INR 257.67 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 148,800 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 384,000 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 256,800 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 349,200 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,315,200 Price\Range: INR 105 Transaction Features: Regulation S
Board Change • Aug 06High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Executive Director Naitik Harsoda is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.